Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Multi-center, Randomized Controlled Clinical Study to Evaluate the Efficacy and Safety of CBP-201 in Chinese Subjects With Moderate to Severe Atopic Dermatitis

NCT05017480 is registered in ClinicalTrials.gov with Connect Biopharm LLC as lead sponsor.

NCT NCT05017480
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05017480 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Multi-center, Randomized Controlled Clinical Study to Evaluate the Efficacy and Safety of CBP-201 in Chinese Subjects With Moderate to Severe Atopic Dermatitis
Lead sponsor
Connect Biopharm LLC
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2021
Completion date
September 28, 2023
Enrollment
330 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

moderate-to-severe atopic dermatitis